Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants
Conditions
Interventions
LY4100511
Rabeprazole
Locations
2
United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Alliance for Multispecialty Research, LLC
Knoxville, Tennessee, United States
Start Date
April 8, 2025
Primary Completion Date
January 1, 2026
Completion Date
January 1, 2026
Last Updated
October 20, 2025
NCT07310901
NCT06342713
NCT07401472
NCT07412353
NCT07280858
NCT07300189
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
CONTACT
clinical_inquiry_hub@lilly.comLead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions